netFormulary NHS
Demonstration Formulary
 Search
 Results

Looking for Pembrolizumab found 18 matches

   


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (08.01.05)
link in drug section NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab (08.01.05)
link in drug section NICE TA428:Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (08.01.05)
link in drug section NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (08.01.05)
link in drug section NICE TA519: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (08.01.05)
link in drug section NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (08.01.05)
link in drug section NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (08.01.05)
link in drug section NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (08.01.05)
link in drug section NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (08.01.05)
link in drug section NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (08.01.05)
link in drug section NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
link in drug section NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (08.01.05)
link in drug section NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (08.01.05)
link in drug section NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (08.01.05)


 
netFormulary